SPECT imaging of pre- and postsynaptic dopaminergic alterations in l-dopa–untreated PD
Abstract
Background: In PD, presynaptic dopamine transporters are known to be decreased, whereas postsynaptic striatal D2 receptors are proposed to be upregulated. However, the relationship between these alterations is not clear.
Objective: To evaluate the ability of SPECT to detect both the pre- and postsynaptic dopaminergic alterations of the striatum in patients with l-dopa–untreated PD.
Methods: We studied 10 l-dopa–untreated patients with clinically mild PD and 21 age-matched normal controls. Individuals had both presynaptic [123I]β-CIT dopamine transporter and postsynaptic [123I]IBF D2 SPECT studies 1 week apart.
Results: In PD patients, the dopamine transporter binding potential Rv ipsilateral/contralateral to the most affected limbs was 30%/41%, 41%/50%, and 59%/68% lower than controls for caudate, anterior putamen, and posterior putamen, respectively. These bilateral Rv decreases showed a lateralized difference more reduced in the contralateral striatum as well as intrastriatal differences most reduced in the posterior putamen. In contrast, in PD patients the D2 binding potential Rv ipsilateral/contralateral was 15%/16% higher for caudate, 18%/14% higher for anterior putamen, and 28%/31% higher for posterior putamen. These bilateral Rv increases showed no lateralized differences and less marked intrastriatal differences. The motor Unified Parkinson’s Disease Rating Scale scores negatively correlated with dopamine transporter Rv but not with D2 Rv.
Conclusions: SPECT imaging can detect characteristic dopaminergic alterations in the striatum of dopa-untreated PD patients including the upregulation of postsynaptic D2 receptors (denervation supersensitivity). SPECT is widely available and is a promising clinical tool to evaluate PD patients.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
German DC, Manaye K, Smith WK, Woodward DJ, Saper CB. Midbrain dopaminergic cell loss in Parkinson’s disease : computer visualization. Ann Neurol 1989;26:507–514.
2.
Fearnley JM, Lees AJ. Aging and Parkinson’s disease : substantia nigra regional selectivity. Brain 1991;114:2283–2301.
3.
Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease : pathophysiologic and clinical implications. N Engl J Med 1988;318:876–880.
4.
Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz O. Receptor basis for dopaminergic supersensitivity in Parkinson’s disease. Nature 1978;273:59–61.
5.
Guttman M, Seeman P. l-dopa reverses the elevated density of D2 dopamine receptors in Parkinson’s diseased striatum. J Neural Transm 1985;64:93–103.
6.
Schwarz J, Tatsch K, Arnold G, et al. 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology 1992;42:556–561.
7.
Ichise M, Ballinger JR. SPECT imaging of dopamine receptors. J Nucl Med 1996;37:1591–1595.
8.
Innis RB, Seibyl JP, Scanley BE, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA 1993;90:11965–11969.
9.
Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I]β-CIT striatal uptake correlates with symptom severity in Parkinson’s disease. Ann Neurol 1995;38:589–598.
10.
Marek KL, Seibyl JP, Zoghbi SS, et al. [123I]β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology 1996;46:231–237.
11.
Neumeyer JL, Wang SY, Milius RA, et al. [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane : high-affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem 1991;34:3144–3146.
12.
Ichise M, Kim YJ, Erami SS, et al. Functional morphometry of the striatum in Parkinson’s disease on three-dimensional surface display of I-123-β-CIT SPECT data. J Nucl Med 1999;40:530–538.
13.
Laulumaa V, Kuikka JT, Soininen H, Bergström K, Länsimies E, Riekkinen P. Imaging of D2 dopamine receptors of patients with Parkinson’s disease using single photon emission computed tomography and iodobenzamide I-123. Arch Neurol 1993;50:509–512.
14.
Antonini A, Schwarz J, Oertel WH, Beer HF, Madeja UD, Leenders KL. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson’s disease : influence of l-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 1994;44:1325–1329.
15.
Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson’s disease : a study with positron emission tomography and [11C]raclopride. Mov Disord 1997;12:33–38.
16.
Rinne JO, Laihinen A, Rinne UK, Nåegren K, Bergman J, Ruotsalainen U. PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson’s disease. Mov Disord 1993;8:134–138.
17.
Sawle GV, Playford ED, Brooks DJ, Quinn N, Frackowiak RS. Asymmetrical pre-synaptic and post-synaptic changes in the striatal dopamine projection in dopa naive parkinsonism : diagnostic implications of the D2 receptor status. Brain 1993;116:853–867.
18.
Wenning GK, Donnemiller E, Granata R, Riccabona G, Poewe W. 123I-β-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson’s disease. Mov Disord 1998;13:438–445.
19.
Brücke T, Wenger S, Asenbaum S, et al. Dopamine D2 receptor imaging and measurement with SPECT. Adv Neurol 1993;60:494–500.
20.
Rutgers AW, Lakke JP, Paans AM, Vaalburg W, Korf J. Tracing of dopamine receptors in hemiparkinsonism with positron emission tomography (PET). J Neurol Sci 1987;80:237–248.
21.
Laruelle M, Wallace E, Seibyl JP, et al. Graphical, kinetic, and equilibrium analyses of in vivo [123I]β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994;14:982–994.
22.
Laruelle M, van Dyck C, Abi-Dargham A, et al. Compartmental modeling of iodine-123-iodobenzofuran binding to dopamine D2 receptors in healthy subjects. J Nucl Med 1994;35:743–754.
23.
Ichise M, Ballinger JR, Golan H, et al. Noninvasive quantification of dopamine D2 receptors with iodine-123-IBF SPECT. J Nucl Med 1996;37:513–520.
24.
Ichise M, Ballinger JR, Vines D, Tsai S, Kung HF. Simplified quantification and reproducibility studies of dopamine D2-receptor binding with iodine-123-IBF SPECT in healthy subjects. J Nucl Med 1997;38:31–37.
25.
Lang AE, Fahn S. Assessment of Parkinson’s disease. In: Munsat TL, ed. Quantification of neurologic deficit. Boston:Butterworths, 1989:285–309.
26.
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease : a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–184.
27.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state” : a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
28.
Francis PT, Sims NR, Procter AW, Bowen DM. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer’s disease : investigative and therapeutic perspectives. J Neurochem 1993;60:1589–1604.
29.
Baldwin RM, Zea-Ponce Y, Zoghbi SS, et al. Evaluation of the monoamine uptake site ligand [123I]methyl 3β-(4-iodophenyl)-tropane-2β-carboxylate ([123I]β-CIT) in non-human primates : pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. Nucl Med Biol 1993;20:597–606.
30.
Armitage P, Berry G. Comparison of several groups: multiple comparisons. In: Statistical methods in medical research. 2nd ed. London:Blackwell Scientific Publications, 1996:200–205.
31.
Guttman M, Burkholder J, Kish SJ, et al. [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson’s disease : implications for the symptomatic threshold. Neurology 1997;48:1578–1583.
32.
Pierot L, Desnos C, Blin J, et al. D1 and D2-type dopamine receptors in patients with Parkinson’s disease and progressive supranuclear palsy. J Neurol Sci 1988;86:291–306.
33.
Cortes R, Camps M, Gueye B, Probst A, Palacios JM. Dopamine receptors in human brain : autoradiographic distribution of D1 and D2 sites in Parkinson syndrome of different etiology. Brain Res 1989;483:30–38.
34.
Quik M, Spokes EG, Mackay AV, Bannister R. Alterations in [3H]spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in the Shy-Drager syndrome and Parkinson’s disease. J Neurol Sci 1979;43:429–437.
35.
Perlmutter JS. New techniques in neuroimaging : when are pretty pictures clinically useful? Curr Opin Neurol 1993;6:889–890.
36.
Todd RD, Carl J, Harmon S, O’Malley KL, Perlmutter JS. Dynamic changes in striatal dopamine D2 and D3 receptor protein and mRNA in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) denervation in baboons. J Neurosci 1996;16:7776–7782.
37.
Leenders KL, Aquilonius SM, Bergström K, et al. Unilateral MPTP lesion in a rhesus monkey : effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers. Brain Res 1988;445:61–67.
38.
Graham WC, Clarke CE, Boyce S, Sambrook MA, Crossman AR, Woodruff GN. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis). Brain Res 1990;514:103–110.
39.
Drugs for Parkinson’s disease reviewed. Drug Ther Bull 1995;33:49–52.
40.
Paetsch PR, Greenshaw AJ. Down-regulation of beta-adrenergic and dopaminergic receptors induced by 2-phenylethylamine. Cell Mol Neurobiol 1993;13:203–215.
41.
Pizzolato G, Chierichetti F, Rossato A, et al. Dopamine receptor SPET imaging in Parkinson’s disease : a [123I]-IBZM and [99mTc]-HM-PAO study. Eur Neurol 1993;33:143–148.
Information & Authors
Information
Published In
Copyright
© 1999.
Publication History
Received: September 16, 1998
Accepted: December 12, 1998
Published online: April 1, 1999
Published in issue: April 1, 1999
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Staged Screening Identifies People with Biomarkers Related to Neuronal Alpha‐Synuclein Disease, Annals of Neurology, 97, 4, (730-740), (2024).https://doi.org/10.1002/ana.27158
- Preclinical evaluation of [18F]FP-CIT, the radiotracer targeting dopamine transporter for diagnosing Parkinson’s disease: pharmacokinetic and efficacy analysis, EJNMMI Research, 14, 1, (2024).https://doi.org/10.1186/s13550-024-01121-6
- The complex molecular pharmacology of the dopamine D2 receptor: Implications for pramipexole, ropinirole, and rotigotine, Pharmacology & Therapeutics, 245, (108392), (2023).https://doi.org/10.1016/j.pharmthera.2023.108392
- Dopamine, Neurochemistry in Clinical Practice, (1-23), (2022).https://doi.org/10.1007/978-3-031-07897-2_1
- Dopamine D2L receptor density influences the recruitment of β-arrestin2 and Gi1 induced by antiparkinsonian drugs, Neuropharmacology, 207, (108942), (2022).https://doi.org/10.1016/j.neuropharm.2022.108942
- Olfactory Bulb D2/D3 Receptor Availability after Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson’s Disease, Toxins, 14, 2, (94), (2022).https://doi.org/10.3390/toxins14020094
- Dopaminergic imaging in degenerative parkinsonisms, an established clinical diagnostic tool, Journal of Neurochemistry, 164, 3, (346-363), (2022).https://doi.org/10.1111/jnc.15561
- Corticobasal Degeneration, Hybrid PET/MR Neuroimaging, (373-386), (2021).https://doi.org/10.1007/978-3-030-82367-2_32
- Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson’s disease trial, BMC Neurology, 21, 1, (2021).https://doi.org/10.1186/s12883-021-02470-8
- Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson’s Disease, Toxins, 13, 7, (505), (2021).https://doi.org/10.3390/toxins13070505
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.